Raquel Crespo

Catchet-MS identifies thalidomide analogues targeting IKZF1 as novel HIV-1 latency reversal agents by reversing latency in CD4+ T-cells.

This study identifies 10 novel host factors involved in HIV latency using a haploid genetic screen and validates their roles through functional assays and drug testing.

The paper identifies gliotoxin as a novel LRA that disrupts 7SK snRNP, releases P-TEFb, and reverses HIV-1 latency in CD4+ T cells.